Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.
BRCA1/2
PALB2
homologous recombination deficiency
mutations
pancreatic cancer
platinum-based chemotherapy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
08
2021
accepted:
31
01
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Mutations in homologous recombination (HR) and Fanconi anemia (FA) genes may predispose to pancreatic cancer (PC) and enable the prediction of sensitivity to platinum-based chemotherapy. FOLFIRINOX is a standard treatment option for non-selected PC patients and could be effective due to undiagnosed DNA repair deficiency. Here, we aimed to determine the frequency of mutations in genes involved in the HR and FA pathways, evaluate their clinical implications, and determine the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of PC patients treated with platinum. We performed targeted DNA sequencing of 30 genes ( In Mutations in the
Sections du résumé
Background
UNASSIGNED
Mutations in homologous recombination (HR) and Fanconi anemia (FA) genes may predispose to pancreatic cancer (PC) and enable the prediction of sensitivity to platinum-based chemotherapy. FOLFIRINOX is a standard treatment option for non-selected PC patients and could be effective due to undiagnosed DNA repair deficiency. Here, we aimed to determine the frequency of mutations in genes involved in the HR and FA pathways, evaluate their clinical implications, and determine the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of PC patients treated with platinum.
Methods
UNASSIGNED
We performed targeted DNA sequencing of 30 genes (
Results
UNASSIGNED
In
Conclusion
UNASSIGNED
Mutations in the
Identifiants
pubmed: 35309086
doi: 10.1177/17588359221083050
pii: 10.1177_17588359221083050
pmc: PMC8928350
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359221083050Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Genome Med. 2019 Aug 23;11(1):53
pubmed: 31443733
J Gastrointest Oncol. 2019 Aug;10(4):703-711
pubmed: 31392051
BMC Biol. 2009 May 14;7:23
pubmed: 19442261
Cancer Res. 2006 Aug 15;66(16):8109-15
pubmed: 16912188
Pharmacol Ther. 2015 May;149:124-38
pubmed: 25512053
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Am J Hum Genet. 2018 Aug 2;103(2):171-187
pubmed: 30032986
Chin Clin Oncol. 2017 Jun;6(3):30
pubmed: 28705007
Cancer Chemother Pharmacol. 2015 Sep;76(3):489-498
pubmed: 26126726
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572943
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
Cancer. 2018 Apr 1;124(7):1374-1382
pubmed: 29338080
Cancer Sci. 2011 Apr;102(4):663-9
pubmed: 21205087
Invest New Drugs. 2018 Feb;36(1):163-169
pubmed: 28782087
Cancer Res. 2017 Nov 1;77(21):e31-e34
pubmed: 29092934
Hum Mutat. 2020 Jan;41(1):81-102
pubmed: 31553106
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Gastroenterology. 2016 Jan;150(1):48-63
pubmed: 26385075
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
JCO Precis Oncol. 2019 Dec;3:1-10
pubmed: 35100730
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074
pubmed: 29506128
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457
pubmed: 33845462
Eur J Cancer. 2018 Jan;89:19-26
pubmed: 29223478
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
JAMA Oncol. 2020 May 1;6(5):724-734
pubmed: 32191290
J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102
pubmed: 33406487
Br J Cancer. 2020 Feb;122(3):333-339
pubmed: 31787751
EMBO J. 2016 May 2;35(9):909-23
pubmed: 27037238
Curr Opin Oncol. 1997 Jan;9(1):88-93
pubmed: 9090499
Bioinformatics. 2009 Sep 1;25(17):2283-5
pubmed: 19542151
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 1996 Dec 1;56(23):5360-4
pubmed: 8968085
Clin Cancer Res. 2013 Jul 1;19(13):3396-403
pubmed: 23658460
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669